TMO

Thermo Fisher Scientific Inc.

$679.38

-1.54% 2026-10-19

Health CareS&P 500

1M 3M 6M 1Y 2Y

TMOSPY

+2.6%

+4.3%

+29.2%

+29.4%

YTD

+17.6%

+26.5%

Grades vs sector

Momentum

51st pct in sector

C+

12-1 return: +19.4%
Percentile within its GICS sector across the S&P 1500.

Growth

61st pct in sector

B-

Revenue growth (YoY): +10.5%
Percentile within its GICS sector across the S&P 1500.

Value

22nd pct in sector

Forward E/P: 4.0% · EBITDA/EV: 4.0%
Percentile within its GICS sector across the S&P 1500.

Profitability

65th pct in sector

Profit margin: +15.0% · Return on equity: +13.5%
Percentile within its GICS sector across the S&P 1500.

Revisions

no data

–

EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Not held by any of our 3 live models right now.

Momentum Top 15

rank 149 of 499 · 12-1 momentum % 27.6

Quality Growth

not ranked (outside this model's universe or screens)

Momentum Blend

not in the current book

Key stats

Market cap$251.2B

P/E (trailing)36.6

P/E (forward)24.6

52-week range435.27 – 704.00

Revenue growth (YoY, latest qtr)+10.5%

Dividend yield0.27%

Analyst consensusStrong Buy (26)

Mean price target$690.62 (+2%)

Valuation & fundamentals

Bottom line

Looks expensive

Model read-out from the numbers below, not advice. Score -4 (DCF counts double).

▼DCF (base case)below the price by 59%

▼Forward P/E vs sector24.6x vs median 17.6x

•Piotroski F-score5/9

▼Net debt / EBITDA3.7x

•Analyst target+2% (26 analysts)

Discounted cash flow

Bear

$133

-80%

growth 0% · disc. 9.6% · term. 2.0%

Base

$279

-59%

growth 5% · disc. 8.6% · term. 2.5%

Bull

$489

-28%

growth 8% · disc. 7.6% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal

Today's price assumes free cash flow grows about 14% a year for 10 years.

Implied

+14%/yr

FCF, last 3 yrs

-3%/yr

FCF, last 5 yrs

-2%/yr

Revenue, last 3 yrs

+0%/yr

Revenue, last 5 yrs

+7%/yr

Same inputs as the DCF above: trailing free cash flow 7.3B, 8.6% discount rate, 2.5% growth after year 10, net debt and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.

Edit assumptions · recalculates instantly

Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-27). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.88 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Health Care

P/E (trailing)

sector median 29.9× · 63rd pct

36.6×
pricier

Forward P/E

sector median 17.6× · 72nd pct

24.6×
pricier

EV / EBITDA

sector median 15.8× · 85th pct

27.9×
pricier

Price / sales

sector median 3.1× · 70th pct

5.4×
pricier

Price / book

sector median 3.5× · 64th pct

4.8×
pricier

FCF yield

sector median 4.1% · 34th pct

2.9%
pricier

Forward EPS $27.58 vs trailing $18.58 (+48% expected growth). Forward P/E uses analysts' next-12-month estimate.

Backlog (remaining performance obligations)

RPO

$29.7B

as of 2026-06-27

vs a year ago

+19%

YoY

× TTM revenue

0.64×

coverage

24-09

24-12

25-03

25-06

25-09

25-12

26-03

26-06

Contracted revenue not yet recognized, from SEC filings (XBRL tag RevenueRemainingPerformanceObligation).

Quality & financial health

Gross margin

–

Operating margin

17.6%

FCF margin

15.8%

Net margin

15.0%

Return on equity

13.2%

Return on invested capital

8.2%

Net debt / EBITDA

3.7×

Current ratio

1.6×

Interest cover

5.6×

Cash conversion (OCF/NI)

1.3×

Piotroski F-score 5/9 · last two fiscal years

✓ Positive net income✓ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✗ Long-term debt / assets fell✓ Current ratio improved✓ No share dilution✗ Gross margin improved✗ Asset turnover improved

Analysts

Mean target

$691

+2%

Analysts

Strong Buy

Range

$560–$800

low – high

● price · ◆ mean target

Annual history

FY	Revenue	Net income	Free cash flow
2025	$44.6B	$6.7B	$6.3B
2024	$42.9B	$6.3B	$7.3B
2023	$42.9B	$6.0B	$6.9B
2022	$44.9B	–	$6.9B
2021	$39.2B	–	$6.8B
2020	$32.2B	–	$6.8B

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR -0.3%.

Earnings

Next report: 2026-10-21 · before open · EPS est 6.40

EstimateActual (beat)Actual (miss)

Report	EPS est	Actual	Surprise
2026-07-23	5.71	6.03	+5.6%
2026-04-23	5.24	5.44	+3.8%
2026-01-29	6.45	6.57	+1.9%
2025-10-22	5.50	5.79	+5.3%
2025-07-23	5.23	5.36	+2.5%
2025-04-23	5.10	5.15	+0.9%
2025-01-30	5.94	6.10	+2.7%
2024-10-23	5.25	5.28	+0.5%

Quarterly revenue

Quarter	Revenue	YoY
2026-06-30	$12.0B	+10.5%
2026-03-31	$11.0B	–
2025-12-31	$12.2B	–
2025-09-30	$11.1B	–
2025-06-30	$10.9B	–

Analyst actions

Morgan Stanley

2026-10-13 · main

Overweight → Overweight
PT $730

TD Cowen

2026-10-13 · main

Buy → Buy
PT $760

Barclays

2026-10-07 · main

Overweight → Overweight
PT $750

CLSA

2026-09-03 · init

→ Outperform
PT $748

Piper Sandler

2026-07-27 · main

Neutral → Neutral
PT $600

Morgan Stanley

2026-07-27 · main

Overweight → Overweight
PT $650

Recent dividends

2026-09-15: $0.470 · 2026-06-15: $0.470 · 2026-03-13: $0.470 · 2025-12-15: $0.430 · 2025-09-15: $0.430 · 2025-06-13: $0.430 · 2025-03-14: $0.430 · 2024-12-13: $0.390

Insider trades

Pettiti Gianluca

President & COO · 2026-08-31

SELL
$245.8K

Pettiti Gianluca

President & COO · 2026-08-31

SELL
$2.3M

Casper Marc N

Director, Chairman & CEO · 2026-08-24

SELL
$63.2K

Casper Marc N

Director, Chairman & CEO · 2026-08-24

SELL
$20.7K

Casper Marc N

Director, Chairman & CEO · 2026-08-24

SELL
$49.6K

Casper Marc N

Director, Chairman & CEO · 2026-08-24

SELL
$39.0K

Casper Marc N